125 related articles for article (PubMed ID: 16036240)
1. Determinants of HAART discontinuation among injection drug users.
Kerr T; Marshall A; Walsh J; Palepu A; Tyndall M; Montaner J; Hogg R; Wood E
AIDS Care; 2005 Jul; 17(5):539-49. PubMed ID: 16036240
[TBL] [Abstract][Full Text] [Related]
2. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
[TBL] [Abstract][Full Text] [Related]
3. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
4. The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study.
Small W; Wood E; Betteridge G; Montaner J; Kerr T
AIDS Care; 2009 Jun; 21(6):708-14. PubMed ID: 19806487
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
[TBL] [Abstract][Full Text] [Related]
6. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users.
Tun W; Gange SJ; Vlahov D; Strathdee SA; Celentano DD
Clin Infect Dis; 2004 Apr; 38(8):1167-74. PubMed ID: 15095224
[TBL] [Abstract][Full Text] [Related]
7. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
8. Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users.
Mehta SH; Lucas G; Astemborski J; Kirk GD; Vlahov D; Galai N
AIDS Care; 2007 May; 19(5):637-45. PubMed ID: 17505924
[TBL] [Abstract][Full Text] [Related]
9. Poor adherence to HIV monitoring and treatment guidelines for HIV-infected injection drug users.
Wood E; Kerr T; Zhang R; Guillemi S; Palepu A; Hogg RS; Montaner JS
HIV Med; 2008 Aug; 9(7):503-7. PubMed ID: 18484977
[TBL] [Abstract][Full Text] [Related]
10. Utility of the Millon Behavioral Medicine Diagnostic (MBMD) to predict adherence to highly active antiretroviral therapy (HAART) medication regimens among HIV-positive men and women.
Cruess DG; Minor S; Antoni MH; Millon T
J Pers Assess; 2007 Dec; 89(3):277-90. PubMed ID: 18001228
[TBL] [Abstract][Full Text] [Related]
11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
12. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
13. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
[TBL] [Abstract][Full Text] [Related]
14. Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users.
Loughlin A; Metsch L; Gardner L; Anderson-Mahoney P; Barrigan M; Strathdee S
AIDS Care; 2004 May; 16(4):485-500. PubMed ID: 15203416
[TBL] [Abstract][Full Text] [Related]
15. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.
Cicconi P; Cozzi-Lepri A; Castagna A; Trecarichi EM; Antinori A; Gatti F; Cassola G; Sighinolfi L; Castelli P; d'Arminio Monforte A;
HIV Med; 2010 Feb; 11(2):104-13. PubMed ID: 19732176
[TBL] [Abstract][Full Text] [Related]
16. Validity of self-reported adherence among injection drug users.
Kerr T; Hogg RS; Yip B; Tyndall MW; Montaner J; Wood E
J Int Assoc Physicians AIDS Care (Chic); 2008; 7(4):157-9. PubMed ID: 18626123
[TBL] [Abstract][Full Text] [Related]
17. The dynamics of injection drug users' personal networks and HIV risk behaviors.
Costenbader EC; Astone NM; Latkin CA
Addiction; 2006 Jul; 101(7):1003-13. PubMed ID: 16771892
[TBL] [Abstract][Full Text] [Related]
18. 'Simply forgot' is the most frequently stated reason for missed doses of HAART irrespective of degree of adherence.
Barfod TS; Sørensen HT; Nielsen H; Rodkjaer L; Obel N
HIV Med; 2006 Jul; 7(5):285-90. PubMed ID: 16945072
[TBL] [Abstract][Full Text] [Related]
19. Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients.
Roca B; Gómez CJ; Arnedo A
J Infect; 2000 Jul; 41(1):50-4. PubMed ID: 10942640
[TBL] [Abstract][Full Text] [Related]
20. Health related quality of life among both current and former injection drug users who are HIV-infected.
Préau M; Protopopescu C; Spire B; Sobel A; Dellamonica P; Moatti JP; Carrieri MP;
Drug Alcohol Depend; 2007 Jan; 86(2-3):175-82. PubMed ID: 16930864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
